Author : Narjis Hadi Al-Saadi and Aziz H. Jasim

Prostate cancer is now recognized as one of the most important medical problems facing the male population and it is one of the most common cancer types. In Iraq prostate cancer is the first most common cancer before all cancer, this reason led us to investigate the prostate tumor markers for detection prostate cancer. In advanced stages, the prostate cancer is metastasis and arrived to bone, this led to lose of bone mineral density (BMD) and cause osteoporosis; therefore we measured urinary deoxypyridinoline (DPD) as a marker of collagen degradation activity, in metastasis prostate cancer patients, in addition we measured prostate specific antigen (PSA) serum total-alkaline phosphatase activity, and calcium, and phosphate as minerals of bone. This study included 50 patients with prostate tumor and 30 healthy subjects as control. Patients were classified according to stage of tumor. Patients with benign prostate hyperplasia (B.P.H), patients with metastasis prostate cancer (M.P.C), and patients with localized prostate cancer (L.P.C). The results showed a highly significant (P<0.000) increase in the level of PSA, DPD, Ca2+ and PO43- and there was a highly significant (P<0.01) increase in the activity of T-ALP in patients with prostate tumor compared with the healthy subject. In addition the results revealed a high significant (P<0.000) increase in the levels of DPD , PSA in patients with M.P.C compared with L.P.C and B.P.H patients, also there was a high significant (P<0.01) increase in the levels of Ca2+ and PO43- in patients with M.P.C compared with L.P.C and B.P.H patients. The data suggest that serial monitoring of deoxypyridinoline (DPD) could be clinically useful as marker of metastatic bone tumors and for treatment monitoring.

Keywords: Prostate cancer, Deoxypyridinoline, Bone markers, Prostate specific antigen, Bone metastasis.